Table 3.
Comparison of the immunohistochemical results in the surgically resected specimens between the clinical progressive disease (cPD) and control groups
| Molecule (localization) | Number of cases (%) | P a | ||
|---|---|---|---|---|
| Immunohistochemically positive | ||||
| cPD group (pre‐NAC, n = 12) | cPD group (post‐NAC, n = 22) | Control group (n = 80) | ||
| CK5/6 (cytoplasm) | 3 (25) | 9 (41) | 4 (5) | <0.001 |
| EGFR (membrane) | NE | 8 (36) | 24 (30) | 0.568 |
| BRCA1 loss (nucleus) | NE | 6 (27) | 29 (36) | 0.43 |
| Basal‐like (EGFR or CK5/6) | NE | 12 (55) | 25 (31) | 0.044 |
| ZEB1 (nucleus) | 2 (16) | 7 (32) | 10 (13) | 0.031 |
| TWISTNB (nucleus) | NE | 6 (27) | 2 (3) | 0.0011 |
| Vimentin (cytoplasm) | 9 (75) | 17 (77) | 43 (54) | 0.047 |
| E‐cadherin loss(cell membrane) | 5 (42) | 9 (41) | 26 (32) | 0.46 |
| Snail‐2 (nucleus) | 9 (41) | 13 (59) | 38 (48) | 0.33 |
| HMGB1 (cytoplasm) | 12 (100) | 19 (86) | 41 (51) | 0.0023 |
| AR (nucleus) | 1 (8) | 2 (9) | 23 (29) | 0.046 |
NE, not expamined.
There was no statistically significant difference between the pre‐NAC and post‐NAC marker positivity of the cPD group.
a
P‐values were calculated for the post‐NAC cPD and control groups.